A scientist from the University of Massachusetts Medical School recently found a way to improve photodynamic therapy, which basically makes use of specific light molecules to target cancer tumors. This is a relatively new discovery in the medical industry, but it is fast getting traction thanks to the multitude of potential applications.
Gang Han, Ph.D. is the one who designed the new way to take advantage of photodynamic therapy to improve upon it along with his team, Phys.org reports. Trained in biochemistry & molecular pharmacology, Han is an associate professor at the university.
He and his team explained how the carbazole-substituted BODIPY (Car-BDP) can vastly improve the results of photodynamic therapy thanks to its NIR absorption band. Since its singlet oxygen quantum yield is exceedingly high, it leads to some unique results.
"This study signals a major step forward in photodynamic therapy by developing a new class of NIR-absorbing biodegradable organic nanoparticles for a highly effective targeting and treatment of deep-tissue tumors," Han said.
The results of the study were posted on the Journal of the American Chemical Society, where Han explains that after using the PLA–PEG-FA, which is a highly biodegradable polymer to encapsulate Car-BDP, the compound formed nanoparticles that possessed small, uniformed, organic, and water-soluble properties and is able to target tumors.
This helps overcome one of the bigger challenges that stop the wider adoption of photodynamic therapy, which is how shallow the penetration to tissue is right now. Normally, this is addressed via the introduction of drugs that are non-toxic and sensitive to light. Once the drug is inside the body, a laser is tuned with the molecules of the substances in the drug, which then targets the tumor.
Han and his team are proposing to make the whole thing simpler using Car-BDP and pairing it with a lamp light that has low power density. The molecules released by this method can be tracked as well, which makes monitoring which tumors have been targeted much easier.


Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
AI-Guided Drones Transform Ukraine’s Battlefield Strategy
TSMC Accuses Former Executive of Leaking Trade Secrets as Taiwan Prosecutors Launch Investigation
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Quantum Systems Projects Revenue Surge as It Eyes IPO or Private Sale
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Taiwan Opposition Criticizes Plan to Block Chinese App Rednote Over Security Concerns
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 



